AIMS/HYPOTHESIS: The objective of the study was to investigate risk factors and develop risk equations for end-stage renal disease (ESRD) in Chinese patients with type 2 diabetes. SUBJECTS AND METHODS: A prospective cohort of 4,438 patients with type 2 diabetes mellitus and without ESRD (median observation period 2.9 years, interquartile range 1.6-4.1 years) was included in the analysis. The end-point (ESRD) was defined by: (1) death due to diabetes with renal manifestations or renal failure; (2) hospitalisation due to renal failure; (3) estimated GFR (eGFR) <15 ml min(-1) 1.73 m(-2). Cox proportional hazards regression was used to develop risk equations. The data were randomly and evenly divided into the training data for development of the risk equations and the test data for validation. The validation was performed using the area under the receiver operating characteristic curve (aROC), which takes into account follow-up time and censoring. RESULTS: During the observation period, 159 patients or 12.45 per 1,000 person-years (95% CI 10.52-14.37 per 1,000 person-years) developed ESRD. Known duration of diabetes, systolic blood pressure, log(10) total cholesterol:HDL cholesterol ratio and retinopathy were significant predictors of ESRD. After further adjusting for eGFR, log(10) spot albumin:creatinine ratio (ACR) and haematocrit, only eGFR, haematocrit and log(10) ACR remained as independent predictors of ESRD. The risk equation derived from these three independent predictors had good discrimination, with an aROC of 0.97. CONCLUSIONS/ INTERPRETATION: Estimated GFR, haematocrit and ACR were independent predictors of ESRD and the derived risk equation performed well in Chinese patients with type 2 diabetes.
AIMS/HYPOTHESIS: The objective of the study was to investigate risk factors and develop risk equations for end-stage renal disease (ESRD) in Chinese patients with type 2 diabetes. SUBJECTS AND METHODS: A prospective cohort of 4,438 patients with type 2 diabetes mellitus and without ESRD (median observation period 2.9 years, interquartile range 1.6-4.1 years) was included in the analysis. The end-point (ESRD) was defined by: (1) death due to diabetes with renal manifestations or renal failure; (2) hospitalisation due to renal failure; (3) estimated GFR (eGFR) <15 ml min(-1) 1.73 m(-2). Cox proportional hazards regression was used to develop risk equations. The data were randomly and evenly divided into the training data for development of the risk equations and the test data for validation. The validation was performed using the area under the receiver operating characteristic curve (aROC), which takes into account follow-up time and censoring. RESULTS: During the observation period, 159 patients or 12.45 per 1,000 person-years (95% CI 10.52-14.37 per 1,000 person-years) developed ESRD. Known duration of diabetes, systolic blood pressure, log(10) total cholesterol:HDL cholesterol ratio and retinopathy were significant predictors of ESRD. After further adjusting for eGFR, log(10) spot albumin:creatinine ratio (ACR) and haematocrit, only eGFR, haematocrit and log(10) ACR remained as independent predictors of ESRD. The risk equation derived from these three independent predictors had good discrimination, with an aROC of 0.97. CONCLUSIONS/ INTERPRETATION: Estimated GFR, haematocrit and ACR were independent predictors of ESRD and the derived risk equation performed well in Chinese patients with type 2 diabetes.
Authors: A Y T Wu; N C T Kong; F A de Leon; C Y Pan; T Y Tai; V T F Yeung; S J Yoo; A Rouillon; M R Weir Journal: Diabetologia Date: 2004-12-23 Impact factor: 10.122
Authors: A P S Kong; W Y So; C C Szeto; N N Chan; A Luk; R C W Ma; R Ozaki; V W S Ng; C S Ho; C W K Lam; C C Chow; C S Cockram; J C N Chan; P C Y Tong Journal: Kidney Int Date: 2006-01 Impact factor: 10.612
Authors: Yoshio N Hall; Chi-yuan Hsu; Carlos Iribarren; Jeanne Darbinian; Charles E McCulloch; Alan S Go Journal: Kidney Int Date: 2005-11 Impact factor: 10.612
Authors: Temduang Chuahirun; Jan Simoni; Cathy Hudson; Timothy Seipel; Apurv Khanna; Ronald B Harrist; Donald E Wesson Journal: Am J Med Sci Date: 2004-02 Impact factor: 2.378
Authors: Peter C Tong; Ka-Fai Lee; Wing-Yee So; Margaret H Ng; Wing-Bun Chan; Matthew K Lo; Norman N Chan; Juliana C Chan Journal: Diabetes Care Date: 2004-01 Impact factor: 19.112
Authors: X L Yang; W Y So; A P S Kong; C S Ho; C W K Lam; M H L Ng; R R Lyu; D D Yin; C C Chow; C S Cockram; P C Y Tong; J C N Chan Journal: Diabetologia Date: 2007-04-13 Impact factor: 10.122
Authors: Gary T Ko; Wing-Yee So; Peter C Tong; Francois Le Coguiec; Debborah Kerr; Greg Lyubomirsky; Beaver Tamesis; Troels Wolthers; Jennifer Nan; Juliana Chan Journal: BMC Med Inform Decis Mak Date: 2010-05-13 Impact factor: 2.796
Authors: Xilin Yang; WingYee So; Gary T C Ko; Ronald C W Ma; Alice P S Kong; Chun-Chung Chow; Peter C Y Tong; Juliana C N Chan Journal: CMAJ Date: 2008-08-26 Impact factor: 8.262
Authors: Guozhi Jiang; Andrea O Luk; Claudia H T Tam; Risa Ozaki; Cadmon K P Lim; Elaine Y K Chow; Eric S Lau; Alice P S Kong; Baoqi Fan; Ka Fai Lee; Shing Chung Siu; Grace Hiu; Chiu Chi Tsang; Kam Piu Lau; Jenny Y Leung; Man-wo Tsang; Grace Kam; Ip Tim Lau; June K Li; Vincent T Yeung; Emmy Lau; Stanley Lo; Samuel Fung; Yuk Lun Cheng; Chun Chung Chow; Nelson L S Tang; Yu Huang; Hui-yao Lan; Richard A Oram; Cheuk Chun Szeto; Wing Yee So; Juliana C N Chan; Ronald C W Ma Journal: Diabetes Date: 2022-03-01 Impact factor: 9.461
Authors: Brian Lee; Marianne Turley; Di Meng; Yvonne Zhou; Terhilda Garrido; Alan Lau; Linda Radler Journal: BMC Health Serv Res Date: 2012-08-15 Impact factor: 2.655
Authors: Colman S C Fung; Weng Yee Chin; Daisy S K Dai; Ruby L P Kwok; Eva L H Tsui; Yuk Fai Wan; Wendy Wong; Carlos K H Wong; Daniel Y T Fong; Cindy L K Lam Journal: BMC Fam Pract Date: 2012-12-05 Impact factor: 2.497
Authors: Xilin Yang; Ronald C Ma; Wing-Yee So; Gary T Ko; Alice P Kong; Christopher W Lam; Chun-Shun Ho; Clive S Cockram; Vivian C Wong; Peter C Tong; Juliana C Chan Journal: Cardiovasc Diabetol Date: 2007-12-02 Impact factor: 9.951
Authors: Xilin Yang; Ronald C Ma; Wing-Yee So; Alice P Kong; Gary T Ko; Chun-Shun Ho; Christopher W Lam; Clive S Cockram; Peter C Tong; Juliana C Chan Journal: Cardiovasc Diabetol Date: 2008-04-22 Impact factor: 9.951